Print

AVEG 014C

A Multicenter, Randomized, Placebo-Controlled, Double-blind Trial to Evaluate the Safety and Immunogenicity of the Therion Recombinant Vaccinia-HIV-1 IIIB env/gag/pol Vaccine (TBC-3B) and MN rgp120/HIV in Alum (VaxGen)

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) June 07, 1993
TBC-3B,MN rgp120 Vaccinia env and gag/pol IIIB; Env gp120 B
TBC-3B Viral Vector - Pox
MN rgp120 Protein
USA 36
NCT00000866
https://clinicaltrials.gov/show/NCT00000866